Kauvar DS, Lefering R, Wade CE. Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma. 2006;60(6 Suppl):S3-11.
CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant hemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010 Jul 3;376(9734):23-32.
Becker BF, Chappell D, Jacob M. Endothelial glycocalyx and coronary vascular permeability: the fringe benefit. Basic Res Cardiol. 2010 Sep;105(6):687-701.
Rahbar E, Cardenas JC, Baimukanova G, et al. Endothelial glycocalyx shedding and vascular permeability in trauma: an observational and mechanistic study. J Trauma Acute Care Surg. 2015 Jul;79(1):55–61.
Johansson PI, Stensballe J, Ostrowski SR. Shock induced endotheliopathy (SHINE) in acute critical illness—a unifying path-ophysiologic mechanism. Crit Care. 2017;21(1):25.
Rady MY, Smithline HA, Blake H, Nowak R, Rivers E. A comparison of the shock index and conventional vital signs to identify acute, critical illness in the emergency department. Ann Emerg Med. 1994;24(4):685–690.
McNab A, Burns B. Shock Index. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
CRASH-2 Collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096-1101.
CRASH-3 Trial Collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet. 2019;394(10210):1713-1723.
Shakur-Still H, et al. Tranexamic acid in trauma: how should we use it? Curr Opin Anaesthesiol. 2020;33(2):221–227.
Ker K, Roberts I, Shakur H, Coats T. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2015;(5):CD004896.